ArticleFrontiers in immunology2019
Interleukin-35 Dampens CD8
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Systematic Review of Interleukin-35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention.Mediators of inflammation · 2025Pooled it
- Unlocking the secrets of NPSLE: the role of dendritic cell-secreted CCL2 in blood-brain barrier disruption.Frontiers in immunology · 2024Pooled it
- Reprogramming Tumor-Associated Macrophages via Targeted NAT10 Inhibition to Enhance Colorectal Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting TIMM23 to overcome osteosarcoma chemoresistance.Cell death & disease · 2025Article
- Liver immunology: Biological role and clinical significance.World journal of hepatology · 2025Review
- CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma.Journal of nanobiotechnology · 2025Article
- Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC.Cell death & disease · 2025Article
- The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLC.Apoptosis : an international journal on programmed cell death · 2025Article
- Defining gastric cancer ecology: the crucial roles of TREM2Communications biology · 2025Article
- Elucidating the role of S100A10 in CD8Cell death & disease · 2024Article
- Single-cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism-related mechanisms.Clinical and translational medicine · 2024Article
- Estimation of the tissue and serum levels of IL-35 in Mycosis fungoides: a case-control study.Archives of dermatological research · 2024Article
- Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B.Biomolecules & biomedicine · 2023Article
- Reduced circulating interleukin 35 is associated with enhanced peripheral T cell function in primary biliary cholangitis.Biomolecules & biomedicine · 2023Article
- Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8Archivum immunologiae et therapiae experimentalis · 2022Article
- Serum Interleukins as Potential Prognostic Biomarkers in HBV-Related Acute-on-Chronic Liver Failure.Mediators of inflammation · 2022Review
- Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.Clinical and experimental immunology · 2021Article
- IL-12 Family Cytokines in Cancer and Immunotherapy.Cancers · 2021Review
- IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.Frontiers in immunology · 2021Review
- Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-35 is a newly identified IL-12 cytokine family member, which has been demonstrated to induce immunotolerance by suppression of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.